

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Equality impact assessment – Scoping

Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5073]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
No

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
N/A

3. Has any change to the draft scope been agreed to highlight potential equality issues?
N/A

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
No

Approved by Associate Director (name): Ross Dent
Date: 26/09/2024

Health Technology Evaluation: Scoping
Equality impact assessment for the Single Technology Appraisal of durvalumab for treating
limited-stage small-cell lung cancer after chemoradiation [ID5073]